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A B S T R A C T
Metastasis is the primary cause of death in prostate cancer (PCa) patients. Small nucleolar
RNAs (snoRNAs) have long been considered “housekeeping” genes with no relevance for
cancer biology. Emerging evidence has challenged this assumption, suggesting that
snoRNA expression is frequently modulated during cancer progression. Despite this, no
study has systematically addressed the prognostic and functional significance of snoRNAs
in PCa.
We performed RNA Sequencing on paired metastatic/non-metastatic PCa xenografts
derived from clinical specimens. The clinical significance of differentially expressed snoR-
NAs was further investigated in two independent primary PCa cohorts (131 and 43 patients,
respectively). The snoRNA demonstrating the strongest association with clinical outcome
was quantified in PCa patient-derived serum samples and its functional relevance was
investigated in PCa cells via gene expression profiling, pathway analysis and gene
silencing.
Our comparison revealed 21 differentially expressed snoRNAs in the metastatic vs. non-
metastatic xenografts. Of those, 12 were represented in clinical databases and were further
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analyzed. SNORA55 emerged as a predictor of shorter relapse-free survival (results
confirmed in two independent databases). SNORA55 was reproducibly detectable in serum
samples from PCa patients. SNORA55 silencing in PCa cell lines significantly inhibited cell
proliferation and migration. Pathway analysis revealed that SNORA55 expression is signif-
icantly associated with growth factor signaling and pro-inflammatory cytokine expression
in PCa.
Our results demonstrate that SNORA55 up-regulation predicts PCa progression and that
silencing this non-coding gene affects PCa cell proliferation and metastatic potential,
thus positioning it as both a novel biomarker and therapeutic target.
ª 2015 The Authors. Published by Elsevier B.V. on behalf of Federation of European
Biochemical Societies. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Prostate cancer (PCa) is a heterogeneous disease that consti-
tutes themost frequently diagnosed neoplasm inNorth Amer-
ican males (Siegel et al., 2012). Patients with localized PCa can
be treated by radical prostatectomy or radiotherapy, often
resulting in complete disease remission. Conversely, the
vast majority of PCa-related deaths result from progression
of localized disease to metastatic castration-resistant PCa
(mCRPC) (Kirby et al., 2011). Despite recent therapeutic ad-
vancements (Bishr and Saad, 2013), mCRPC remains an incur-
able disease. Novel insights into PCa progression might
therefore identify more effective therapeutic targets. In addi-
tion, clinico-pathological factors such as T (tumor) stage, Glea-
son score and prostate-specific antigen (PSA) are still the gold
standard for PCa prognostication. However, it has been shown
that their discriminatory value for identifying potentially le-
thal disease is limited (D’Elia et al., 2014). As a result, the dis-
covery of more effective and potentially non-invasive
prognostic biomarkers is of paramount importance.
Recent analyses have revealed that most RNA molecules
produced in human cells are not translated into proteins
(Kapranov et al., 2007). Included among these non-coding
transcripts are microRNAs, which have emerged as critical
mediators of cancer progression (Di Leva et al., 2014) and
potentially useful biomarkers in oncology (Watahiki et al.,
2013, 2011), as well as long non-coding RNAs (lncRNAs) and
small nucleolar RNAs (snoRNAs). Many research groups,
including ours, have identified numerous PCa-associated
lncRNAs (Chakravarty et al., 2014; Crea et al., 2014b; Iyer
et al., 2015; Prensner et al., 2014). Indeed it has been shown
that the PCA3 lncRNA is detectable in biological fluids and dis-
criminates PCa patients vs. healthy subjects (Wei et al., 2014),
suggesting that the latter two classes of non-coding RNAsmay
also be useful as biomarkers.
On the contrary, snoRNAs are a poorly investigated class of
non-coding RNAs that are encoded by at least 400 distinct
genomic regions. They have traditionally been considered
“housekeeping” genes, mainly involved in alternative splicing
and ribosomal RNA (rRNA) modifications (Martens-Uzunova
et al., 2013). In light of their presumptive stable expression,
some snoRNAs have been selected as reference genes in
studies investigating the expression of microRNAs in human
neoplasm (Gee et al., 2011). However, recent findings have
challenged these assumptions, revealing that snoRNAs can
migrate to the cytoplasm and modulate a wide range of
cellular functions (Taulli and Pandolfi, 2012). At the same
time, it has become evident that snoRNA expression patterns
are deregulated in cancer cells and in serum samples from
cancer patients (Baraniskin et al., 2013). In addition, some
snoRNAs are emerging as critical mediators of cancer progres-
sion. For example SNORA42 is often amplified in lung cancer,
and its silencing leads to cancer cell apoptosis, thereby
impairing in vivo cancer growth (Mei et al., 2012). SNORD50A
is frequently deleted and acts as a tumor suppressor in breast
cancer and PCa (Dong et al., 2009, 2008). This gene also repre-
sents, to date, the only functionally characterized snoRNA
in PCa.
We have utilized novel patient tumor tissue-derived xeno-
graft models to identify snoRNAs that were differentially
expressed in non-metastatic versus metastatic xenografts
derived from the primary tumor of one patient. Differentially
expressed snoRNAs were then queried in a test cohort of PCa
patients to identify their correlation with disease progression
and prognosis. These analyses revealed that SNORA55 was
reproducibly associated with worse PCa outcome. In addition,
we found that SNORA55 is required for PCa proliferation and
migration. Taken together our studies support the hypothesis
that SNORA55may be a novel prognostic biomarker, as well as
a novel therapeutic target, in PCa.
2. Patients and methods
2.1. Patient-derived prostate cancer xenografts
The generation and propagation of the LTL313B and LTL313H
tumor tissue xenograft models, as well as their characteriza-
tion and their use in identification of differentially expressed
transcripts, has been described previously (Watahiki et al.,
2011) (Wang et al., 2005) (Crea et al., 2014b). Tumor tissue
was accrued under UBC/BCCA REB protocol #: H04-60131 and
engraftment was performed according to the University of
British Columbia Animal Care Committee protocol: A10-0100.
2.2. RNA sequencing
Total RNA extraction, RNA Sequencing and transcript annota-
tion have been described previously, and have been performed
on one sample per model (Crea et al., 2014b). Importantly for
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this project, total RNA was extracted using Trizol, a method
that preserves small RNAs (Rio et al., 2010). Reverse transcrip-
tionwas performed using randomhexamers (Otogenetics, Oto-
Rseq2-20N). In addition, transcript annotation (DNA Nexus)
was performed using 36 nt alignment sequences, which are
much shorter than the typical snoRNA length (70e120 nt)
(Stepanov et al., 2015). Gene expressionwas quantified through
the RPKM value reads per kilobase of transcript per million
mapped reads (Mortazavi et al., 2008). RPKM values were
normalized to the root mean square (RMS) for each sample.
All genes annotated as “non-coding” were further filtered to
exclude microRNAs, ribosomal RNAs, transfer RNAs, piwi-
interacting RNAs and long non-coding RNAs. The
remaining transcripts contained 372 typical small nucleolar
RNAs and 24 small Cajal body RNAs (scaRNAs), which were
selected for further characterization. Collectively, classical
small nucleolar RNAs and scaRNAs are denoted as
“snoRNAs” in this manuscript. Differential expression of
SNORA55was confirmed on an independentmicroarray exper-
iment (LTL-313H vs. LTL-313B), which is publically available:
http://www.livingtumorcentre.com/GeneExpression/search
form.php.
2.3. Database analysis
Selected snoRNAs were analyzed through the cBio cancer
genomic portal (Cerami et al., 2012). This database includes
clinico-pathological and gene expression information from
29 normal prostate, 131 primary and 19 metastatic PCa
samples (Taylor et al., 2010). Samples containing more
than 70% neoplastic cells based on histological assessment
were used for RNA extraction. Metastatic cases were
defined as those having clinical or pathological evidence
of cancer dissemination to any of the following: lymph
nodes, bones or soft tissues (lung, brain, spine, testis).
Annotated clinical data from patients who underwent
radical prostatectomy was available including PSA every
three months for the first year post-prostatectomy, semi-
annually for the second year and annually thereafter.
Recurrence-free survival (RFS) was calculated as the time
between prostatectomy and the occurrence of two,
consecutive rising plasma PSA values  0.2 ng/ml (Mottet
et al., 2011).
Gene expression data were downloaded from the portal
as log2 whole transcript normalized RNA expression
values (Affymetrix Human Exon 1.0 ST arrays). For survival
analysis (log-rank test), Z score vs. normal values were
employed, since this is the only option available in the portal.
The optimal Z score threshold was determined as the one giv-
ing the lowest p value (Z score range: 2  0.25). Based on these
criteria, a Z score > 2.25 was indicated as “high” SNORA55
expression.
Significance Analysis of Microarray data (SAM) was per-
formed in R using the MSKCC database and clinical and gene
expression information available through the cBio portal.
We identified 663 positively associated and 220 negatively
associated genes (Q < 0.001%, fold change higher than 2).
Genes positively associated with SNORA55 were then
uploaded in Ingenuity Pathway Analysis (Ingenuity Systems,
www.ingenuity.com).
2.4. Clinical samples
2.4.1. Validation dataset
Samples from 43 PCa patients treated with primary radical
prostate-vesiculectomy with pelvic lymph node sampling
were collected at the Stephanshorn Clinic in St. Gallen
Switzerland, following study protocol approval by the local
ethics committee (Protocol number: ZeTuP19/04). Resected
specimens were immediately transferred on ice to the Insti-
tute for Pathology of the Kantons Hospital, St. Gallen for ex-
amination. Small tissue samples from macroscopically
visible tumor and non-tumor prostate tissue were dissected,
snap frozen in liquid nitrogen and cryo-preserved at 80 C.
Samples were cut in a cryo-microtome and a slide of each
probe was stained with hematoxylin-eosin for histological
verification. Localized PCa cases were defined as those with
no clinical or pathological evidence of metastatic diffusion.
PSA measurements were performed pre-operation, and after
operation every 6  2 months. Recurrence-free survival was
calculated as the time between prostatectomy and the occur-
rence of two, consecutive rising plasma PSA values  0.2 ng/
ml. RNA was isolated from frozen materials using the TRI-
reagent (Ambion) method according to the manufacturer’s
guidelines. cDNA was synthesized from 1 mg of total RNA us-
ing Superscript II RNase H-reverse transcriptase and DNAse
digestion (Invitrogen).
2.4.2. Serum samples from PCa patients
Serum samples from patients with newly diagnosed prostate
cancer were collected at the Royal Surrey and Frimley Park
Hospital, Guildford, UK. All samples were collected prior to
any prostate cancer treatment. Patients donated samples
following a process of informed consent and an ethical
approval granted by the NHS Ethics Committee number 08/
H1306/115. Healthy controls (males 45 years old or younger)
were recruited and assessed for absence of clinical signs of
prostatic neoplasms, including normal PSA levels, as
described (Crea et al., 2014b). Control subjects’ age was chosen
to minimize the possibility of occult PCa, which is very infre-
quent in males younger than 45 (Aubert et al., 1991).
2.5. Quantitative PCR (qPCR)
qPCR was performed on RNA extracted and reverse-
transcribed from the validation and serum sample datasets.
For the validation dataset, we employed TaqMan gene expres-
sion assays and performed the PCR reaction as previously
described (Crea et al., 2011). SNORA55, TNF and GHRHR expres-
sion (Applied Biosystems assays: Hs03298696_s1,
Hs01113624_g1, Hs00173457_m1, respectively) was normal-
ized to HPRT1 (Applied Biosystems assay: Hs01003267_m1)
and quantified through the 2DDCt method. HPRT1 was chosen
because its expression was identified as the most stable
among a panel of putative reference genes tested in normal
and neoplastic tissues (including PCa samples) (de Kok et al.,
2005). Since we intended to validate gene expression data ob-
tained in a different platform and expressed in different unit
of measure (Z scores fromMSKCC database) we dichotomized
SNORA55 expression based on the expression level that most
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efficiently predicted relapse-free survival (lowest p value, log
rank-test; at least 5 patients in the smaller group). RNA
derived from the serum samples was reverse transcribed us-
ing the NCode VILO cDNA Synthesis kit (Applied Biosystems).
For quantification, we employed the SNORA55 TaqMan assay
as described above. Mir-30e (assay number: 000602) was
used as the internal reference, since we have previously
described this gene as the most stably expressed circulating
small RNA in PCa patients (Watahiki et al., 2013).
2.6. In vitro experiments
PCa cell lines were grown in appropriate cell culture media
and screened for SNORA55 expression, as previously described
(Crea et al., 2014b). Second-generation (20OMe/PS gapmers)
antisense oligonucleotides (ASOs) specifically targeting
SNORA55 were designed and produced by Integrated DNA
Technologies, based on the mature sequence of SNORA55
(Gene ID: 677834). The negative control ASO was designed to
avoid silencing of any knownhuman transcript. ASO transfec-
tion was performed as previously described (Narita et al.,
2008). Cell proliferation and percentage of cell death were
measured on Trypan Blue stained cells using a TC20 Auto-
mated Cell Counter (Bio-Rad). Cell migration was measured
using a wound healing assay, as previously described by our
laboratory (Chiang et al., 2014). The following modifications
were introduced to the protocol: cells were transfected with
ASO1 or NC; pictures were taken 0, 12, 18, 30, 36 and 48 h
post transfections. For the highly migrating DU145 cell line,
pictures were taken till full “healing” of the NC-treated cells
(20 h). Cell fractionation and dihydrotestosterone (DHT) treat-
ment of LNCaP cells have been previously described (Parolia
et al., 2015).
2.7. Statistical analysis
Unless otherwise specified, all statistical analyses were per-
formed using Graph Pad Prism 6 software (La Jolla, CA).
MSKCC database clinical annotation and gene expression
levels (available through Cbio portal) were used to dichoto-
mize all patients in 2 groups: high SNORA55 expression
(threshold as described in “Database analysis”) vs. low
SNORA55 expression (all other patients).
3. Results
3.1. Small nucleolar RNA transcriptome analysis of
matched non-metastatic and metastatic PCa xenografts
Identification of metastasis-associated genes in primary PCa
using patient samples is a major challenge due to the hetero-
geneity of such specimens. They typically consist of subpopu-
lationswith differentmetastatic abilities, making it difficult to
identify genes with critical roles in the development of metas-
tasis (Fidler, 2002; Lin et al., 2010). For these reasons, molecu-
lar “signatures” for metastatic PCa have been extremely
difficult to identify. To overcome these hurdles, we developed
a multi-step profiling strategy to identify snoRNAs associated
with PCa progression (Figure 1A). First, we profiled snoRNAs in
a paired localized/metastatic tumor tissue PCa xenograft
model (Watahiki et al., 2011) that has already been exploited
to successfully identify miRNAs (Watahiki et al., 2011) and
long-non-coding RNAs (Crea et al., 2014b) associated with
PCa progression. Our analysis showed that the global expres-
sion profiles of protein-coding and non-coding RNAs were
very similar in Metastatic vs. Non-Metastatic PCa xenografts,
indicating that no general alteration in the synthesis of these
two kinds of RNAs was associated with PCa progression
(Suppl. Figure 1). Notably, snoRNAs and ribonuclear-
associated RNAs were the most abundantly expressed tran-
scripts in both tumor tissue lines. We identified a total of
396 snoRNAs expressed in at least one PCa xenograft. Of those,
15 were up-regulated and 6 down-regulated in Metastatic vs.
Non-Metastatic PCa xenografts (Table 1). These transcripts
were further analyzed in clinical samples.
3.2. Expression profile of snoRNAs in clinical samples
In order to validate and establish the clinical relevance of our
RNA Sequencing data, we analyzed differentially expressed
snoRNAs though the cBio MSKCC database, which holds
gene expression and clinical data from a collection of 131
localized and 19 metastatic PCa samples, as well as 29 benign
prostatic tissues (Cerami et al., 2012; Taylor et al., 2010). We
found that 12 out of 21 differentially expressed snoRNAs
were represented in this database (Table 1). We hypothesized
that snoRNAs up-regulated in the metastatic xenograft could
contribute to PCa progression, and should be therefore up-
regulated in neoplastic vs. normal and/or in metastatic vs.
localized PCa samples. Similarly, the down-regulated snoR-
NAs should also be down-regulated in the clinical database
samples studied. Those transcripts were therefore investi-
gated for correlations with cancer progression and for their
prognostic value. In order to reduce our false discovery ratio,
we applied the Bonferroni correction to all analyses per-
formed on this dataset. We identified 6 snoRNAs with statisti-
cally significant differential expression in normal prostate vs.
localized PCa and/or in metastatic vs. localized PCa (Suppl.
Figure 2; corrected p < 0.05, ANOVA and Tukey’s post-test).
Notably, all differentially expressed transcripts were modu-
lated in accordance to our pre-clinical model’s predictions.
For example SNORA6, which was the most highly up-
regulated snoRNA in our RNA Sequencing database (Table 1),
was progressively up-regulated in normal prostate, localized
PCa and metastatic PCa samples (Suppl. Figure 2A). Similarly,
SNORA55 expression was higher in metastatic PCa xenografts,
and progressively increased in normal prostate, primary PCa
and metastatic PCa samples (Suppl. Figure 2C). The only
snoRNA significantly repressed in metastatic vs. normal PCa
samples was snoRNA31 (SNORA31), which was also down-
regulated in Metastatic vs. Non-Metastatic xenografts (Table
1). These results corroborate the clinical relevance of the tran-
scription profiles derived from our pre-clinical model.
3.3. Diagnostic and prognostic value of SNORA55
In light of our initial findings, we set out to test whether snoR-
NAs were able to predict recurrence-free survival (RFS) when
measured in primary PCa samples at the time of surgery.
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Among the 12 selected snoRNAs (Table 1), only SNORA55 was
associated with clinical outcome. Univariate analysis
(Figure 1B) indicated that PCa samples with SNORA55 up-
regulation displayed a significantly shorter RFS after surgery
(corrected log-rank p ¼ 0.015, median survival ¼ 35.35 vs.
>140 months, 6/11 vs. 21/120 events). Subgroup analysis
revealed no correlation between SNORA55 expression and
ERG fusion status, Gleason grade, T stage or circulating PSA
levels (Suppl. Figure 3AeD).
To further strengthen our analysis, we explored the diag-
nostic and prognostic value of SNORA55 in an independent
dataset including benign prostatic hyperplasia (BPH) and
localized PCa sampleswith long-term follow-up (patient char-
acteristics summarized in Suppl. Tab. 1). In this case, SNORA55
expression was measured by qPCR, using RNA extracted from
primary PCa biopsies at the time of diagnosis. Our analysis
confirmed significant up-regulation of SNORA55 in PCa vs.
BPH samples (Figure 1C; mean expression: 8.345  2.555 vs.
1.342  0.3729, p ¼ 0.0095). We also confirmed that SNORA55
up-regulationwas associatedwith shorter RFS after prostatec-
tomy (Figure 1D; log-rank p value ¼ 0.0054, Hazard Ratio 95%
Confidence interval: 1.134e8.230).
Recent reports indicate that snoRNAs can be detected in
serum samples from cancer patients and that those findings
might have a diagnostic value (Baraniskin et al., 2013). In light
of the prognostic role of SNORA55, we investigated its expres-
sion in a small but homogenous cohort of 9 PCa patients
treated with brachytherapy vs. 5 healthy subjects (Suppl.
Table 2). Our results indicated that circulating SNORA55 is
significantly up-regulated in PCa patients vs. healthy controls
(Figure 1E).
3.4. Functional characterization of SNORA55
Our results to this point indicate that SNORA55 is increasingly
up-regulated during PCa progression, and that higher
SNORA55 expression is associated with poorer prognosis and
worse response to therapy. SNORA55 locus maps on chromo-
some 1p34 and co-localizes with an intron of the PABPC4
protein-coding gene (Figure 2A). Notably, clinical data indicate
that SNORA55 and PABC4 expression profiles are not corre-
lated, and that PABPC4 has no prognostic value in PCa
(Suppl. Figure 4). To investigate the specific role of SNORA55
in PCa biology, we conducted functional experiments in PCa
cell lines. First we screened the expression of this gene in a
panel of human prostatic cell lines (Figure 2B). SNORA55 was
easily detectable (Ct value < 30) in all the investigated cell
lines, with highest expression in LNCaP, an androgen-
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Figure 1 e A, Analytical strategy employed for this study. 21 out of 396 differentially expressed snoRNAs (Met. vs. Non-met. xenografts) were
searched in the MSKCC database containing 267 snoRNAs. 12/21 genes were also represented in this platform and were chosen for further
analyses. The gene(s) associated with PCa prognosis were validated in an independent clinical dataset. B, Relapse-free survival according to
SNORA55 expression in primary tumor at diagnosis, (MSKCC database, dichotomization based on Z score, as described in “Methods”) *p< 0.05
(log rank test, Bonferroni correction). C, SNORA55 expression measured by qPCR in 9 BPH and 43 primary PCa samples. **p< 0.01 (unpaired T
test). D, Relapse-free survival according to SNORA55 expression in primary tumor at diagnosis (qPCR on 43 samples). **p< 0.01 (log rank test).
E, Expression of SNORA55 in serum samples from PCa patients and healthy controls. *p< 0.05 (unpaired, two-sided T test).
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receptor (AR) positive cell line derived from a metastatic PCa
lesion (Horoszewicz et al., 1983). RNA fractionation analyses
revealed that SNORA55 is predominantly nuclear (Figure 2C).
Since the expression of some PCa-associated non-coding
RNAs is regulated by AR activation (Crea et al., 2014b), we
tested this possibility for SNORA55. Data from LNCaP cells
exposed to different DHT concentrations demonstrated that
SNORA55 expression is not controlled by AR activity
(Figure 2D).
Subsequently, we designed three ASOs specifically target-
ing SNORA55 and measured their gene silencing efficacy in
LNCaP cells. ASO1 induced a dose-dependent SNORA55
silencing, when compared with control ASO at the same con-
centration (Figure 3A). ASO1 was therefore selected for func-
tional studies. SNORA55 silencing induced a dose-dependent
inhibition of cell proliferation (Figure 3B). Since our findings
were limited to one AR-positive cell line expressing high levels
of SNORA55, we tested the effects of ASO1 on DU145 cells (AR-
negative cells expressing relatively lower levels of SNORA55).
Our results indicate that SNORA55 silencing in this cell line
induced significant, even if slightly less emphatic, cell growth
inhibition (Figure 3C). In order to elucidate themechanismun-
derlying this growth inhibitory effect, we measured the per-
centage of cell death in DU145 and LNCaP cells exposed to
ASO1 vs. NC. Our results indicate that SNORA55 silencing
significantly increases cell death in both cell lines
(Figure 3D). Notably, this effect is more evident in LNCaP cells.
Similarly, we found that SNORA55 silencing hinders the
migration of both LNCaP and DU145 cells (Figure 4A,B). We
cannot rule out the possibility that reduced migration is at
least in part a consequence of ASO1-induced cell death. How-
ever, the anti-migratory effect is equally emphatic in LNCaP as
in DU145 cells, whereas cell death is more marked in LNCAP
cells. It is therefore conceivable that effect of SNORA55 on
cell migration is at least in part cell death-independent.
3.5. Pathway analysis
Our results indicate that SNORA55 is up-regulated during PCa
progression and that it is functionally relevant for PCa cell
proliferation and migration. Since this gene had never been
associated with cancer before, we investigated the molecular
pathways associated with its expression. To this end, we per-
formed SAM analysis and identified 663 genes significantly
correlated with SNORA55 expression. We designated those
genes as SNORA55-Related Signature (55-RS) and analyzed
them through Ingenuity Pathway Analysis. The 55-RS was
significantly associated with several pathways, including
“Cell-to-Cell Signaling and interaction” and “Cell death and
Survival” (Table 2). The top molecular network associated
with 55-RS was “Protein Synthesis, Cell-to-Cell Signaling and
Interaction, Lipid Metabolism” (Suppl. Figure 5). Notably, tu-
mor necrosis factor (TNF) and growth hormone releasing hor-
mone receptor (GHRHR) occupied a central role in this
molecular network and were highly correlated with SNORA55
expression. In keeping with these predictions, SNORA55
silencing reduced the expression of TNF and, to a lesser
extent, of GHRHR (Suppl. Figure 6).
4. Discussion
In the present study, we identified SNORA55 as a previously
uncharacterized gene that is potentially associated with PCa
progression. Our results were generated through a multi-
step strategy that takes advantage of unique pre-clinical
models developed at the Living Tumor Lab (www.livingtumor-
lab.com). These patient-derived, PCa xenografts accurately
reproduce clinico-pathological and molecular features of the
original neoplasm (Lin et al., 2014). SnoRNAs identified as
differentially expressed in this pre-clinicalmodelwere further
investigated through 2 independent clinical databases (193 to-
tal samples). Our experimental strategy is based on the obser-
vation that PCa samples are generally composed of multi-
clonal subpopulations, each with a peculiar transcriptional
landscape and metastatic potential (Lin et al., 2010; Liu et al.,
2009). PCa heterogeneity often masks the expression profile
of truly metastatic cells, thereby hampering the identification
of an effective prognostic signature. As a consequence, several
multi-genic PCa prognostic algorithms have been described
(Cooperberg et al., 2013; Glinsky et al., 2004; Irshad et al.,
2013; Varambally et al., 2005) but none of them have been
currently integrated in the clinical practice. The only risk
stratificationmethod that is commonly employed is still based
on plasma PSA levels, T stage and Gleason grade (Heidenreich
et al., 2014). The lack of more accurate and easy-to-detect
Table 1 e Differentially expressed snoRNAs (Metastatic vs. Non-
Metastatic PCa xenograft). RMS, root mean square. RPKM, reads
per kilobase of transcript per million mapped reads. We report
transcripts with RMS-normalized RPKM ratio>2 or<0.5
(Metastatic vs. Non-Metastatic xenograft, RNA Seq. data).
Transcripts up-regulated in the metastatic xenograft are in red,
transcripts down-regulated in the metastatic xenograft are in blue.
Transcripts up-regulated in the metastatic xenograft are ranked
based on absolute expression level in LTL313H cells. Transcripts
down-regulated in the non-metastatic xenograft are ranked based on
absolute expression in LTL313B cells.
Gene
name
Met. Non-
met.
RMS-
normalized
RPKM ratio
Represented
in MSKCC
database?
SNORA6 52.24 17.85 3.383431953 Yes
SNORA42 28.86 10.59 3.153692615 Yes
SNORA62 25.9 12.75 2.349627175 Yes
SNORD88A 13.78 6.397 2.491743725 No
SNORA55 10.8 3.559 3.511427723 Yes
SCARNA20 8.448 3.751 2.605070423 No
SNORA11B 8.337 3.166 3.045045045 No
SNORA18 5.064 0.6716 8.721094856 Yes
SNORA45 4.374 1.692 2.990630856 Yes
SNORA72 1.809 0.3358 6.228373702 Yes
SNORA26 1.174 0.3633 3.736551323 No
SNORD33 1.151 0.534 2.490603363 Yes
SNORA22 1.077 0.3333 3.736925515 Yes
SNORD88B 0.9845 0.457 2.492485549 No
SCARNA18 0.7235 0.3358 2.491349481 No
SNORA64 233.5 70.91 0.351062867 Yes
SNORA63 32.83 13.09 0.461068211 No
SNORA81 13.94 4.829 0.400454545 No
SNORA31 4.432 1.102 0.287416587 Yes
SNORA51 4.365 1.447 0.383349468 Yes
SNORA76 2.015 0.7235 0.415312008 No
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prognostic markers hinders an optimal exploitation of the
therapeutic armamentarium against lethal PCa (Cersosimo,
2012).
Our results from two independent clinical datasets demon-
strated that SNORA55 is: 1) easily detectable in PCa specimens,
including serum samples; 2) significantly up-regulated in
neoplastic vs. normal prostatic tissue; and 3) a predictor of
post-prostatectomy outcome. While the first two features
are shared with other investigated snoRNAs, the third is a
distinctive feature of SNORA55. A previous study mainly
focusing on miRNAs also reported that some snoRNAs are
differentially expressed in primary vs. lymph node-derived le-
sions from PCa patients (Martens-Uzunova et al., 2012). In
accordance with our findings, SNORA6 was listed as up-
regulated in metastatic lesions. However, this study did not
address the prognostic and functional value of snoRNAs in
PCa. Another very recent study showed that snoRNA expres-
sion profiles are deregulated during PCa initiation and pro-
gression, and suggested that they can be employed as
prognostic markers (Martens-Uzunova et al., 2015). However,
our report is the first one showing that the expression levels
of a snoRNA (measured in primary PCa specimens) efficiently
predict post-operative PCa prognosis. Notably, the prognostic
value of SNORA55was confirmed in two clinical datasets with
different characteristics: the MSKCC dataset comprises
relatively younger men (median age ¼ 58.3) and lower-grade
neoplasms (percentage of Gleason grade>7 ¼ 9%) (Taylor
et al., 2010), compared to our validation cohort (median
age ¼ 68, percentage of Gleason Grade >7 ¼ 23%).
SnoRNAs have been long considered “housekeeping”
genes, whose only function was to regulate basic cellular pro-
cesses in the nucleus. Recent evidence indicated that snoR-
NAs also contribute to cancer progression through nucleolar
and extra-nucleolar functions (reviewed in Crea et al.
(2014a)). For example, some snoRNAs are able to translocate
into the cytoplasm, where they control reactive oxygen spe-
cies production, thereby fueling chemoresistance and meta-
static progression (Chu et al., 2012; Crea et al., 2014a). Other
snoRNAs generate miRNA-like transcripts, which in turn
regulate the expression of several cancer-related genes (Ono
et al., 2011). Our study shows that SNORA55 is specifically
expressed and functionally relevant in cancer cells. Our gene
expression analysis revealed that, unlike other disease-
associated snoRNAs, SNORA55 is mainly retained in the nu-
cleus. Due to its sub-cellular localization, we could not employ
small interfering RNAs (siRNAs) to target this gene. For this
reason, we silenced its expression via ASOs, which proved
effective in silencing nuclear RNAs (Gutschner et al., 2013).
Our results indicate that SNORA55 is required for PCa cell pro-
liferation and migration. These findings may explain the
Figure 2 e A, Chromosomal localization of SNORA55 (data from Gene Cards). B, SNORA55 expression in prostate cell lines. C, Subcellular
localization of SNORA55 in LNCaP cells (MALAT1 is a nuclear non-coding RNA, actin mRNA is prevalently cytoplasmic). D, Effects of DHT
treatment on SNORA55 expression (LNCaP cells). HPRT1 is an AR-independent gene (negative control), PSA and TMPRSS2 are AR-dependent
genes (positive controls). The experiment was performed as previously described (Parolia et al., 2015).
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strong correlation between SNORA55 expression and PCa
prognosis.
In keepingwith those findings, our Pathway Analysis sheds
new light on the molecular mechanisms by which snoRNAs
may contribute to cancer progression. We found that
SNORA55 expression is significantly associated with known
oncogenic pathways and particularly with the expression of
TNF- and GHRH-dependent signaling (Suppl. Figure 5). The
pro-inflammatory cytokine TNFa is over-expressed in PCa
specimens (Rodriguez-Berriguete et al., 2013), and it may
Figure 3 e A, SNORA55 expression in LNCaP cells exposed to different ASO concentrations (48 h). ***p< 0.001 vs. control (1 way ANOVA and
Tukey multiple comparison post-test, highest concentration of each treatment). B, Relative LNCaP cell count after treatment with different ASO
concentrations (48 h). **p< 0.01 (2 way ANOVA and Sidak post-test). C, Relative DU145 cell count after treatment with ASOs (250 nM, 48 h).
***p< 0.001 (unpaired T test). D, Percentage of cell death in LNCaP and DU145 cells exposed to NC or ASO1 (250 nM, 48 h). *p< 0.05;
**p< 0.01 (unpaired T test).
Figure 4 e LNCaP (A) and Du145 (B) cell migration in cells exposed to control or ASO1 (250 nM). *p< 0.05; **p< 0.01 (2 way ANOVA and
Sidak post-test).
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contribute to prostate carcinogenesis and neoplastic progres-
sion (DeMarzo et al., 2007). Notably, high TNFa expression has
been associated with poor PCa prognosis (Rodriguez-
Berriguete et al., 2013). GHRH was first discovered as a hypo-
thalamic neuropeptide (Bowers, 2012). The GHRH-FSH/LH
axis is primarily responsible for triggering testosterone pro-
duction by the testis. Recent evidence showed that GHRH re-
ceptors are also expressed by PCa cells, and that their
inhibition is an effective therapeutic strategy in PCa pre-
clinical models (Rick et al., 2012). Therefore, the GHRH-
dependent signal transduction pathway is functionally rele-
vant for PCa cells and might mediate the functional role of
SNORA55.
5. Conclusions
The non-coding transcriptome represents a vast and mainly
uncharted region of the human genome whose relevance in
neoplasms has been overlooked for many years. SnoRNAs
are one of the most abundant non-coding RNA classes and
some of them show deregulated expression and/or epigenetic
alterations in human neoplasms (Esteller, 2011; Martens-
Uzunova et al., 2013). Notably, snoRNAs are also detectable
in biological fluids (Baraniskin et al., 2013), a feature that
makes them particularly attractive cancer biomarkers. For
these reasons, some authors have predicted that snoRNAs
will emerge as novel diagnostic and prognostic tools in the
near future (Mannoor et al., 2012). We anticipate that our find-
ings, along with similar studies performed on other neo-
plasms (Gee et al., 2011; Valleron et al., 2012), will pave the
way to the discovery of novel clinically relevant biomarkers
and therapeutic targets in oncology.
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